[Controlled, double blind study of a possible interaction between acemetacin and a concomitant anticoagulant therapy].
In a controlled double blind study, 20 patients undergoing long-term anticoagulant therapy with phenprocoumon received [1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetoxy]acetic acid (acemetacin, TV 1322, Rantudil) concomitantly to establish whether there was any risk of an interaction. Neither the placebo dose nor the concomitant medication with 3 x 60 mg acemetacin had any statistically important influence on thromboplastin value, fibrinogen, phenprocoumon consumption or platelet aggregation. Accordingly, no clinically relevant interaction is to be expected by the concomitant therapy with 3 x 60 mg acemetacin/d and phenprocoumon, or in all probability, with any coumarin compound.